A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.
Latest Information Update: 23 Sep 2024
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms VACCIMMUN
- 23 Sep 2024 Status changed from recruiting to completed.
- 03 Jun 2021 New trial record